| Ms Phylavanh Phanhtharath, ACNS-BC | |
|
1190 Waianuenue Ave, Hilo, HI 96720-2094 | |
| (808) 932-3000 | |
| Not Available |
| Full Name | Ms Phylavanh Phanhtharath |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 14 Years |
| Location | 1190 Waianuenue Ave, Hilo, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265965321 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | APRN-2756 (Hawaii) | Secondary |
| 283X00000X | Rehabilitation Hospital | AP133384 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hilo Medical Center | Hilo, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kau Hospital | 7416945548 | 88 |
News Archive
One of four (26%) working-age U.S. adults experienced a gap in health insurance coverage during 2011, often because they lost or changed jobs, according to a new Commonwealth Fund report that also shows how difficult it is for people to regain health insurance on their own after losing employer-sponsored coverage.
A multi-institution study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that increasing the number of insured patients is not associated with higher intensive care unit (ICU) usage in Massachusetts.
The Children's Hospital of Philadelphia CEO Steven M. Altschuler, Drexel University President John A. Fry, and Hebrew University of Jerusalem President Menahem Ben-Sasson signed a research agreement on November 11 as part of Philadelphia Mayor Michael A. Nutter's trade mission to Israel. The research partnership is designed to focus on pediatric translational research and to develop a collaborative platform for advancing pediatric medicine from the lab to the bedside.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
How easy is it to falsify memory? New research at the Weizmann Institute shows that a bit of social pressure may be all that is needed. The study, which appears Friday in Science, reveals a unique pattern of brain activity when false memories are formed - one that hints at a surprising connection between our social selves and memory.
› Verified 7 days ago
| Entity Name | Kau Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144304338 PECOS PAC ID: 7416945548 Enrollment ID: O20040601000398 |
News Archive
One of four (26%) working-age U.S. adults experienced a gap in health insurance coverage during 2011, often because they lost or changed jobs, according to a new Commonwealth Fund report that also shows how difficult it is for people to regain health insurance on their own after losing employer-sponsored coverage.
A multi-institution study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that increasing the number of insured patients is not associated with higher intensive care unit (ICU) usage in Massachusetts.
The Children's Hospital of Philadelphia CEO Steven M. Altschuler, Drexel University President John A. Fry, and Hebrew University of Jerusalem President Menahem Ben-Sasson signed a research agreement on November 11 as part of Philadelphia Mayor Michael A. Nutter's trade mission to Israel. The research partnership is designed to focus on pediatric translational research and to develop a collaborative platform for advancing pediatric medicine from the lab to the bedside.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
How easy is it to falsify memory? New research at the Weizmann Institute shows that a bit of social pressure may be all that is needed. The study, which appears Friday in Science, reveals a unique pattern of brain activity when false memories are formed - one that hints at a surprising connection between our social selves and memory.
› Verified 7 days ago
| Entity Name | Hilo Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962584060 PECOS PAC ID: 1254422900 Enrollment ID: O20070809000268 |
News Archive
One of four (26%) working-age U.S. adults experienced a gap in health insurance coverage during 2011, often because they lost or changed jobs, according to a new Commonwealth Fund report that also shows how difficult it is for people to regain health insurance on their own after losing employer-sponsored coverage.
A multi-institution study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that increasing the number of insured patients is not associated with higher intensive care unit (ICU) usage in Massachusetts.
The Children's Hospital of Philadelphia CEO Steven M. Altschuler, Drexel University President John A. Fry, and Hebrew University of Jerusalem President Menahem Ben-Sasson signed a research agreement on November 11 as part of Philadelphia Mayor Michael A. Nutter's trade mission to Israel. The research partnership is designed to focus on pediatric translational research and to develop a collaborative platform for advancing pediatric medicine from the lab to the bedside.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
How easy is it to falsify memory? New research at the Weizmann Institute shows that a bit of social pressure may be all that is needed. The study, which appears Friday in Science, reveals a unique pattern of brain activity when false memories are formed - one that hints at a surprising connection between our social selves and memory.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Phylavanh Phanhtharath, ACNS-BC 1190 Waianuenue Ave, Hilo, HI 96720-2094 Ph: (808) 932-3000 | Ms Phylavanh Phanhtharath, ACNS-BC 1190 Waianuenue Ave, Hilo, HI 96720-2094 Ph: (808) 932-3000 |
News Archive
One of four (26%) working-age U.S. adults experienced a gap in health insurance coverage during 2011, often because they lost or changed jobs, according to a new Commonwealth Fund report that also shows how difficult it is for people to regain health insurance on their own after losing employer-sponsored coverage.
A multi-institution study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that increasing the number of insured patients is not associated with higher intensive care unit (ICU) usage in Massachusetts.
The Children's Hospital of Philadelphia CEO Steven M. Altschuler, Drexel University President John A. Fry, and Hebrew University of Jerusalem President Menahem Ben-Sasson signed a research agreement on November 11 as part of Philadelphia Mayor Michael A. Nutter's trade mission to Israel. The research partnership is designed to focus on pediatric translational research and to develop a collaborative platform for advancing pediatric medicine from the lab to the bedside.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
How easy is it to falsify memory? New research at the Weizmann Institute shows that a bit of social pressure may be all that is needed. The study, which appears Friday in Science, reveals a unique pattern of brain activity when false memories are formed - one that hints at a surprising connection between our social selves and memory.
› Verified 7 days ago